Medazepam

Debilitated patients: Dose reduction required.

Glaucoma.

Severe hepatic impairment. Elderly or debilitated patients; muscle weakness or myasthenia gravis; impaired liver or kidney function; predisposition to seizures; depression; severe respiratory dysfunction; sleep apnoea; movement disorders; drowsiness may affect skilled tasks; history of alcohol or drug addiction. Treatment withdrawal should be gradual. Avoid long-term use. Pregnancy and lactation.

Fatigue, drowsiness, dizziness, prolonged reaction time, headache, coordination disorders (ataxia), confusion, anterograde amnesia. Rarely, GI symptoms, laryngeal spasm, chest pain, hypotension, bradycardia, depression, decreased libido, increased appetite, dry mouth, muscle weakness, respiratory failure.

Additive CNS depression or sedative effects with drugs that have CNS depressant properties e.g. alcohol, antidepressants, sedating antihistamines, antipsychotics, general anaesthetics, other hypnotics or sedatives, opioid analgesics, cisapride.
Potentially Fatal: Increased risk of toxicity with hepatic microsomal enzyme inhibitors.

Description:
Mechanism of Action: Medazepam is a long-acting benzodiazepine used for the short-term treatment of anxiety disorders.
Pharmacokinetics:
Absorption: Absorbed rapidly from the GI tract (oral); peak plasma concentrations after 1-2 hr.
Metabolism: Hepatic; metabolised to diazepam and desmethyldiazepam.

Anxiolytics